Research Appraisalother

Network pharmacology and machine learning reveal multi-target mechanisms of poly herbal formulation against atherosclerosis

Pakistan journal of pharmaceutical sciencesShafique, Muhammad, Umer Ghori, Muhammad, Hassan, Mubashir et al.1 May 2026DOI

Clinical Snapshot

55CEBM
Evidence: Weakother

PICO Framework

P — PopulationComputational models representing atherosclerosis pathways and targets
I — InterventionPoly herbal formulation compounds from Allium sativum, Ginkgo biloba, and Nerium oleander
C — ComparatorNo direct comparator - computational screening study
O — OutcomesIdentification of bioactive compounds and their molecular targets for atherosclerosis treatment

Bottom Line

This computational study identifies potential anti-atherosclerotic compounds from three medicinal plants using network pharmacology and molecular docking approaches. While the methodology appears sound and identifies promising targets including quercetin and naringenin affecting cholesterol metabolism and inflammatory pathways, the study represents early-stage drug discovery research. The findings require extensive experimental validation, including in vitro and in vivo studies, before any clinical application can be considered. Australian clinicians should note that these herbal compounds are not currently approved therapeutic agents for atherosclerosis. The study provides a foundation for future research but does not support immediate clinical recommendations. Patients with cardiovascular disease should continue evidence-based treatments including statins, antiplatelets, and lifestyle modifications as per current guidelines.

Evidence: Weak

Key Findings

  • Effect Size: Not applicable - qualitative computational screening

  • Primary Outcome: Identification of 10 core bioactive compounds with anti-atherosclerotic potential

  • Nnt Or Sensitivity: Molecular docking scores not quantified in abstract

  • Confidence Interval: Not reported

Clinical Application

Low immediate feasibility - requires extensive preclinical and clinical validation before therapeutic application Limited relevance to Australian practice without TGA-approved formulations; potential research interest for complementary medicine development under TGA guidelines Patients with atherosclerosis or cardiovascular risk, pending clinical validation

Abstract

BACKGROUND: Herbs, like Allium sativum, Ginkgo biloba and Nerium oleander are traditional medicinal plants that have been used to treat atherosclerosis and cardiovascular disease. This study provides valuable insights into how network pharmacology (NP) and emerging machine learning are utilized to identify potential drug candidates from these plants for treatment of atherosclerosis. METHODS: NP analysis was employed to screen compounds and their potential gene targets from databases and tools e.g. IMPPAT, PubChem, KNAPSACK, Swiss ADME, Swiss Target Prediction, Disgenet and GeneCard. Cytoscape 3.10.2 was employed to visually understand these networks. DAVID database was used for functional and enrichment analysis of the genes validated through molecular docking using PyRx and Discovery Studio. RESULTS: Computational tools and bioinformatics approaches showed a few core compounds, such as Quercetin, Naringenin, Luteolin, Kaempferol, Apigenin, Daidzein, Luteolin-7-olate, Pinocembrin, Pregnenolone and Fisetin found to be effective against atherosclerosis. Pathway analysis revealed that mechanism of atherosclerosis development is directly associated with cholesterol metabolism, cellular senescence, Ras, NF-κB and PI3K-Akt signaling pathways. CONCLUSION: NP and molecular docking analysis suggested that screened compounds may inhibit progression of atherosclerosis by modulating key associated pathways. Hence, this machine learning aided NP study provides basis for understanding and recognizing the activity of these plants in treating atherosclerosis.

Share:XLinkedIn

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service